Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315079 · ClinicalTrials.gov registry record
Point of Care Testing of Inflammatory Markers in Tears
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 63
- Enrollment target
NCT02315079: Completed study, sponsored by University of Florida.
NCT02315079 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02315079 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
To evaluate the use of a point of care device to measure markers of inflammation in various eye conditions. In particular, matrix metalloproteinase-9 (MMP-9) will be measured. MMP-9 is an enzyme that plays a role in inflammation. The value obtained with the point of care device will be correlated with values obtained using gel electrophoresis to measure MMP-9 from the same sample. These data will be compared to clinical exam findings and questionnaires to help the investigators better understand the role of this marker of inflammation in eye diseases and possibly improve diagnostic abilities.
Interventions
- OTHER Eye inflammation
- OTHER Without eye inflammation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-01 |
What the finished NCT02315079 record still lists
NCT02315079 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Eye inflammation is the first listed.
NCT02315079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02315079 about?
NCT02315079 is a clinical study titled "Point of Care Testing of Inflammatory Markers in Tears". To evaluate the use of a point of care device to measure markers of inflammation in various eye conditions. In particular, matrix metalloproteinase-9 (MMP-9) will be measured. MMP-9 is an enzyme that plays a role in inflammation. The value obtained with the point of care device will be correlated wi...
What is the current status of trial NCT02315079?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2015-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02315079?
The interventions under investigation include: Eye inflammation (OTHER), Without eye inflammation (OTHER).
Who is sponsoring clinical trial NCT02315079?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia